

case study

Data-Driven Patient Identification for IgA Nephropathy Enrollment

Context

Panoramic Health is supporting global enrollment for a Phase III trial in IgA nephropathy (IgAN), a rare kidney disease that often requires proactive patient identification to meet study goals. Given the trial's modest global enrollment target, each site's contribution carried significant weight.

Objectives

The study aims to evaluate a novel investigational therapy in patients with IgAN. Panoramic Health's role is to identify and enroll eligible patients across its network using its advanced data and analytics capabilities.

- **Global enrollment goal:** 150 patients
- **Panoramic enrollment goal:** Not assigned
- **Target population:** Adults with biopsy-confirmed IgA nephropathy

Process

Using its enterprise-wide EMR system, Panoramic Health's central enrollment team proactively identifies potential participants not only at designated research sites but also across affiliated office locations, broadening the pool of eligible patients. EMR-integrated eligibility flags signal treating physicians to refer candidates during routine visits, while dedicated research staff coordinate prescreening, consent, and enrollment to ensure a seamless patient experience.

Impact

By combining advanced analytics with a broad clinical footprint, Panoramic Health is delivering meaningful impact in a rare disease trial, reinforcing its ability to reach hard-to-enroll patients and contribute to study success.

- **11 patients** enrolled to date across **4 sites**
- Currently contributing over **7% of global enrollment**
- Expanding patient access by leveraging nearby practice locations through EMR-integrated screening tools